Skip to content
Clinical Trials – home
Verifiedinfo

University Of Antwerp

Belgium Drie Eikenstraat 663, 2650 Edegem, Belgium

  • 211 trials recruiting
  • Non-small cell lung cancer · Breast cancer metastatic · Metabolic dysfunction-associated steatohepatitis
  • Adults and children

About Specializations

University Of Antwerp in Edegem, Belgium specialises in clinical trials of conditions such as Non-small cell lung cancer, Breast cancer metastatic, Metabolic dysfunction-associated steatohepatitis, Breast cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Oncology and Solid Tumor Research

At the University Of Antwerp, clinical research in oncology focuses on advanced cancers, especially non-small cell lung cancer and colorectal cancer. These studies are designed to test new treatment combinations, compare them with standard care, and better understand how to improve tumor control in difficult-to-treat disease.

  • Advanced and metastatic NSCLC with novel immunotherapy combinations
  • Unresectable or metastatic colorectal cancer with new therapy strategies
  • Evaluation of treatment response and disease control in solid tumors

The overall goal is to expand effective options for patients with aggressive cancers while refining how well current and emerging treatments work.

Pediatric Cancer and Neuroblastoma Studies

A major part of the site’s research addresses high-risk neuroblastoma, a serious childhood cancer. The trials explore ways to improve survival after initial treatment by combining chemotherapy, high-dose treatment approaches, radiotherapy, and added immunotherapy for patients who need stronger disease control.

  • High-risk neuroblastoma in children and adolescents
  • Testing intensified treatment approaches after initial response
  • Adding chemoimmunotherapy for patients with residual disease

These studies aim to improve long-term outcomes and reduce the risk of relapse in a vulnerable pediatric population.

Digestive System and Liver Disease Research

The site also studies digestive system diseases, including Crohn’s disease, ulcerative colitis, and complications of liver cirrhosis. Research here focuses on improving symptom control, preventing complications, and assessing whether new therapies can better support patients with chronic inflammatory or liver-related conditions.

  • Crohn’s disease and ulcerative colitis
  • Alcoholic liver cirrhosis with prevention of hepatic encephalopathy
  • Testing treatment effectiveness and patient safety in chronic gastrointestinal disease

This line of research supports better management of long-term digestive and liver disorders through more effective and better-tolerated care.

Rare Disease and Metabolic Disorder Trials

Clinical studies at University Of Antwerp include work on rare conditions such as Fabry disease. These trials are centered on evaluating whether new enzyme-based treatments can safely improve disease control and offer meaningful benefit for adults living with this inherited disorder.

  • Fabry disease in adults
  • Assessing safety, tolerability, and ongoing treatment benefit
  • Supporting research in congenital and hereditary diseases

The research aims to improve care for patients with uncommon genetic diseases that often require specialized long-term treatment.

Respiratory Virus and Influenza Vaccine Research

A strong research theme at the site is virus diseases and respiratory tract diseases, especially studies of influenza, COVID-19, respiratory syncytial virus, and human metapneumovirus. Much of this work evaluates vaccines and immune responses, with the aim of improving prevention in adults, older adults, and other at-risk groups.

  • Influenza prevention and immune response studies
  • RSV and hMPV vaccine research in older adults
  • COVID-19 vaccine-related innate immune response studies

This research helps determine how well vaccines protect against common and emerging respiratory infections and how the immune system responds over time.

Maternal, Neonatal, and Immune System Research

The site contributes to studies in immune system processes and pregnancy-related health, including research on vaccination during pregnancy and prevention of neonatal infections. These trials examine immune responses in mothers and the potential benefit of maternal vaccination for protecting newborns.

  • Pertussis vaccination in pregnancy
  • Prevention of group B streptococcus infection
  • Evaluating maternal and neonatal immune responses

The focus is on improving protection for both pregnant women and infants through better understanding of vaccine timing and immune response.

Bacterial and Viral Infection Prevention

In addition to respiratory infections, the University Of Antwerp is involved in research on broader infectious disease prevention, including yellow fever, rabies, and avian influenza. These studies are designed to assess vaccine safety, immune response, and protection against serious infections.

  • Yellow fever and rabies vaccine research
  • Avian influenza and other zoonotic infection prevention
  • Testing immune response and vaccine acceptability in healthy adults

This work supports preparedness against infectious threats by improving preventive strategies and understanding how the body responds to vaccination.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Drie Eikenstraat 6632650 EdegemBelgium
Recruiting now
211 trials
Conditions studied
206
Partner status
Verified

More sites in EdegemBelgium

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

493 clinical trials

Asthma

Recruiting
Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Benralizumab
  • Sponsor:AstraZeneca AB
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Golimumab
  • Sponsor:Janssen Cilag International
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alks 2680
  • Sponsor:Alkermes Inc.
Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan Hydrochloride
  • Sponsor:Zai Lab (US) LLC
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alks 2680
  • Sponsor:Alkermes Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Alks 2680
  • Sponsor:Alkermes Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BI 456906
  • Sponsor:Boehringer Ingelheim International GmbH
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Barzolvolimab
  • Sponsor:Celldex Therapeutics Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Exelixis Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Depemokimab
  • Sponsor:Glaxosmithkline Research & Development Limited
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).